Axiom Investment Management LLC Exelixis, Inc. Transaction History

Axiom Investment Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $3,136 - $4,454	200 New	200 $3,000
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $409,840 - $544,260	-23,500 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$17.03 - $22.67 $165,701 - $220,579	-9,730 Reduced 29.28%	23,500 $533,000
Q4 2021 Feb 02, 2022	SELL	$15.84 - $21.88 $47,535 - $65,661	-3,001 Reduced 8.28%	33,230 $608,000
Q3 2021 Oct 18, 2021	SELL	$16.3 - $21.14 $788,088 - $1.02 Million	-48,349 Reduced 57.16%	36,231 $766,000
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $582,818 - $829,907	32,469 Added 62.31%	84,580 $1.54 Million
Q1 2021 May 20, 2021	SELL	$20.53 - $25.22 $61,590 - $75,660	-3,000 Reduced 5.44%	52,111 $1.18 Million
Q1 2021 May 13, 2021	BUY	$20.53 - $25.22 $1.13 Million - $1.39 Million	55,111 New	55,111 $1.25 Million
Q3 2019 Mar 16, 2021	SELL	$17.68 - $22.65 $288,184 - $369,195	-16,300 Closed	0 $0
Q2 2019 Mar 16, 2021	BUY	$18.93 - $24.75 $308,559 - $403,425	16,300 New	16,300 $349,000

507

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Axiom Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Axiom Investment Management LLC with notifications on news.